All In Biotech

Drug Trial Radar · NCT00713830

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea

Last checked: Nov 20, 2026Latest source record: Dec 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 859 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

859

Actual

Start

Jul 2008

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to sulfonylurea without or with metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide when added to sulfonylurea with or without metformin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. The secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than (\<) 7 percent (%); percentage of patients reaching HbA1c less than or equal to (\<=) 6.5%; body weight; fasting plasma glucose (FPG); beta-cell function assessed by homeostasis model assessment (HOMA) beta; 2-hour postprandial plasma glucose (PPG), glucagon, insulin, proinsulin, and C-peptide after a standardized meal challenge test in a sub-study in all patients in selected centers; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Lixisenatide (AVE0010)Drug

    Self administered by subcutaneous injections once daily within the hour preceding breakfast.

  • PlaceboDrug

    Self administered by subcutaneous injections once daily within the hour preceding breakfast.

  • Pen auto-injectorDevice

  • SulfonylureaDrug

    Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.

  • MetforminDrug

    Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Time frame: Baseline, Week 24

Locations

16 sites in 16 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Sofia, Bulgaria

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Cairo, Egypt

  • Sanofi-Aventis Administrative Office

    Berlin, Germany

  • Sanofi-Aventis Administrative Office

    Mumbai, India

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Tokyo, Japan

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Bucharest, Romania

  • Sanofi-Aventis Administrative Office

    Moscow, Russia

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Administrative Office

    Taipei, Taiwan

  • Sanofi-Aventis Administrative Office

    Bangkok, Thailand

  • Sanofi-Aventis Administrative Office

    Mégrine, Tunisia

  • Sanofi-Aventis Administrative Office

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.